Bazedoxifene/Cholecalciferol - Hyundai Pharmaceutical

Drug Profile

Bazedoxifene/Cholecalciferol - Hyundai Pharmaceutical

Alternative Names: HDD0 1614; HOB 078

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class Adjuvants; Azepines; Calcium regulators; Cholestenes; Indoles; Osteoporosis therapies; Phenols; Small molecules; Sterols; Vitamin D analogues
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoporosis

Most Recent Events

  • 31 Jan 2018 Chemical structure information added
  • 05 Jan 2018 Hyundai Pharmaceutical completes a phase I trial for Osteoporosis (In volunteers) in South Korea (NCT03382314)
  • 16 Oct 2017 Phase-I clinical trials in Osteoporosis (In volunteers) in South Korea (unspecified route) (NCT03382314)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top